pancrelipase

FDA Drug Profile — PERTZYE

pancrelipase is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including PERTZYE. Available dosage form: capsule, delayed release.

Drug details

Generic Name
pancrelipase
Brand Names
PERTZYE
Application Number
BLA022175
Sponsor
Digestive Care, Inc.
NDC Codes
4
Dosage Forms
CAPSULE, DELAYED RELEASE
Routes
ORAL
Active Ingredients
PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, PANCRELIPASE PROTEASE

Indications and Usage

1. INDICATIONS AND USAGE VIOKACE, in combination with a proton pump inhibitor, is indicated for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in adults. VIOKACE, in combination with a proton pump inhibitor, is indicated for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in adults. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.